Zobrazeno 1 - 10
of 629
pro vyhledávání: '"Roepcke S"'
Autor:
Li Z; Global Clinical and Translational Sciences, Plasma-Derived Therapies, Takeda Development Center Americas, Inc., Cambridge, MA, United States., Roepcke S; Pharmacometrics, Simulations Plus, Inc., Buffalo, NY, United States., Franke R; Clinical Pharmacology, Cognigen Division of Simulations Plus, Inc., Buffalo, NY, United States., Yel L; Global Clinical Sciences, Takeda Development Center Americas, Inc., Cambridge, MA, United States.
Publikováno v:
Frontiers in neurology [Front Neurol] 2024 Nov 06; Vol. 15, pp. 1478419. Date of Electronic Publication: 2024 Nov 06 (Print Publication: 2024).
Publikováno v:
International Journal of COPD, Vol Volume 15, Pp 1-13 (2020)
Olaf Holz,1,* David S DeLuca,2,* Stefan Roepcke,3 Thomas Illig,2 Klaus M Weinberger,4–6 Christian Schudt,7 Jens M Hohlfeld1,2 1Fraunhofer ITEM, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung R
Externí odkaz:
https://doaj.org/article/4b7294116f1a4045ac5e47f8e7537715
Autor:
Li Z; Clinical Pharmacology & Early Clinical Development, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA., Roepcke S; Pharmacometrics, Cognigen, a division of Simulations Plus, Buffalo, New York, USA., Franke R; Quantitative Clinical Pharmacology, Cognigen, a division of Simulations Plus, Buffalo, New York, USA., Yel L; Clinical Medicine, Takeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.
Publikováno v:
Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2024 Aug; Vol. 11 (8), pp. 1977-1987. Date of Electronic Publication: 2024 Jul 08.
Publikováno v:
International Journal of COPD, Vol 2015, Iss Issue 1, Pp 1393-1402 (2015)
Olaf Holz,1,* Stefan Roepcke,2,* Henrik Watz,3 Uwe Tegtbur,4 Gezim Lahu,2 Jens M Hohlfeld1 1Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM), German Center for Lung Research (DZL, BREATH), Hannover, Germany; 2Takeda Pharmaceutical
Externí odkaz:
https://doaj.org/article/245954b052e24dafb77bbc5c4128827d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Roepcke S; Cognigen Division of Simulations Plus, Inc., Buffalo, New York, USA., Passarell J; Cognigen Division of Simulations Plus, Inc., Buffalo, New York, USA., Walker H; Mundipharma, Cambridge, United Kingdom., Flanagan S; Cidara Therapeutics, San Diego, California, USA.
Publikováno v:
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2023 Dec 14; Vol. 67 (12), pp. e0091623. Date of Electronic Publication: 2023 Nov 28.
Autor:
Bihorel S; Simulation Plus, Cognigen Division, Buffalo, New York, USA., Cao Y; Merck & Co., Inc., Rahway, New Jersey, USA., Chawla A; Merck & Co., Inc., Rahway, New Jersey, USA., Birger R; Merck & Co., Inc., Rahway, New Jersey, USA., Maas BM; Merck & Co., Inc., Rahway, New Jersey, USA., Gao W; Merck & Co., Inc., Rahway, New Jersey, USA., Roepcke S; Simulation Plus, Cognigen Division, Buffalo, New York, USA., Sardella S; Simulation Plus, Cognigen Division, Buffalo, New York, USA., Humphrey R; Simulation Plus, Cognigen Division, Buffalo, New York, USA., Kondragunta S; Simulation Plus, Cognigen Division, Buffalo, New York, USA., Jayaraman B; Simulation Plus, Cognigen Division, Buffalo, New York, USA., Martinho M; Merck & Co., Inc., Rahway, New Jersey, USA., Painter W; Ridgeback Biotherapeutics LP, Miami, Florida, USA., Painter G; Department of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, Georgia, USA., Holman W; Ridgeback Biotherapeutics LP, Miami, Florida, USA., De Anda C; Merck & Co., Inc., Rahway, New Jersey, USA., Brown ML; Merck & Co., Inc., Rahway, New Jersey, USA., Johnson MG; Merck & Co., Inc., Rahway, New Jersey, USA., Paschke A; Merck & Co., Inc., Rahway, New Jersey, USA., Rizk ML; Merck & Co., Inc., Rahway, New Jersey, USA., Stone JA; Merck & Co., Inc., Rahway, New Jersey, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Dec; Vol. 12 (12), pp. 1859-1871. Date of Electronic Publication: 2023 Oct 05.
Autor:
Owen JS; Consulting Department, Cognigen Division of Simulations Plus, Buffalo, NY, USA. joel@pumas.ai., Rackley RJ; Global PK/DM Department, Viatris Inc, Morgantown, WV, USA., Hummel MA; Global PK/DM Department, Viatris Inc, Morgantown, WV, USA., Roepcke S; Pharmacometrics Department, Cognigen Division of Simulations Plus, Buffalo, NY, USA., Huang H; Pharmacometrics Department, Cognigen Division of Simulations Plus, Buffalo, NY, USA., Liu M; Global PK/DM Department, Viatris Inc, Morgantown, WV, USA., Idris TA; Global Clinical Sciences Department, Viatris, Hyderabad, India., Murugesan SMN; Clinical Development & Medical Affairs Department, Biocon Biologics Ltd, Bangalore, Karnataka, India., Marwah A; Clinical Development & Medical Affairs Department, Biocon Biologics Ltd, Bangalore, Karnataka, India., Loganathan S; Clinical Development & Medical Affairs Department, Biocon Biologics Ltd, Bangalore, Karnataka, India., Ranganna G; Global Clinical Sciences Department, Viatris, Bengaluru, India., Barve A; Clinical Development & Medical Affairs, Viatris Inc, Canonsburg, PA, USA., Waller CF; Department of Hematology, Oncology, and Stem Cell Transplantation, University Medical Centre Freiburg and Faculty of Medicine, Freiburg, Germany., Socinski MA; Cancer Institute, Advent Health Cancer Institute, Orlando, FL, USA.
Publikováno v:
European journal of drug metabolism and pharmacokinetics [Eur J Drug Metab Pharmacokinet] 2023 Nov; Vol. 48 (6), pp. 675-689. Date of Electronic Publication: 2023 Oct 04.
Autor:
Sager JE; Vir Biotechnology, Inc., San Francisco, California, USA., El-Zailik A; Vir Biotechnology, Inc., San Francisco, California, USA., Passarell J; Cognigen Division, Simulations Plus, Inc., Buffalo, New York, USA., Roepcke S; Cognigen Division, Simulations Plus, Inc., Buffalo, New York, USA., Li X; GSK, Upper Providence, Pennsylvania, USA., Aldinger M; Vir Biotechnology, Inc., San Francisco, California, USA., Nader A; GSK, Upper Providence, Pennsylvania, USA., Skingsley A; GSK, Brentford, UK., Alexander EL; Vir Biotechnology, Inc., San Francisco, California, USA., Yeh WW; Vir Biotechnology, Inc., San Francisco, California, USA., Mogalian E; Vir Biotechnology, Inc., San Francisco, California, USA., Garner C; Vir Biotechnology, Inc., San Francisco, California, USA., Peppercorn A; GSK, Cambridge, Massachusetts, USA., Shapiro AE; Fred Hutchinson Cancer Center, Seattle, Washington, USA., Reyes M; Vir Biotechnology, Inc., San Francisco, California, USA.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2023 Jun; Vol. 12 (6), pp. 853-864. Date of Electronic Publication: 2023 Apr 06.
Purpose: There is an ongoing demand for easily accessible biomarkers that reflect the physiological and pathophysiological mechanisms of COPD. To test if an exercise challenge could help to identify clinically relevant metabolic biomarkers in COPD. P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______610::a25f959c7df05e5c73b510eb652f87ed
https://publica.fraunhofer.de/handle/publica/263039
https://publica.fraunhofer.de/handle/publica/263039
